Recent progress in obesity pharmacotherapy

Current Opinion in Gastroenterology

Volumn 16, Issue 2, 2000, Pages 166-172

  Ryan, Donna H ^a,b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27644447650     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200003000-00012     Document Type: Article

References (49)

1. Calle E, Thun MJ, Petrelli JM, Rodriguez C, Heath CS: Body mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999, 344:1097-1105. A prospective study of more than 1 million people during 14 years. It demonstrates increased risk from all causes, cardiovascular disease, cancer, or other disease mortality throughout the range of moderate and severe overweight in both men and women of all ages, there being no lessening of risk with advancing age. However, the study shows risk associated with high BMI to be less for blacks than for whites.
2. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL: Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998, 22:39-47.
3. World Health Organization: Obesity-preventing and managing the global epidemic, report of a WHO consultancy on obesity, Geneva, 3-5 June, 1997. Geneva; 1998:WHO/NUT/NCD/98.1.
4. National Institutes of Health, National Heart, Lung and Blood Institute: Clinical guidelines on the identification, evaluation, and treatment of obesity in adults: an evidence report. Obes Res 1998, 6(suppl):51S-210S.
5. Bray GA: Obesity: a time bomb to be diffused [editorial]. Lancet 1998, 352:160-161.
6. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C: Prospective study of intentional weight loss and mortality in never-smoking overweight U.S. white women age 40-64 years. Am J Epidemiol 1995, 141:1128-1141.
7. Colditz GA, Coakley E: Weight, weight gain, activity and major illness: the Nurses Health Study. Int J Sports Med 1997,18(suppl):S162-S1670.
8. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, et al.: Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes mellitus. Ann Surg 1995, 222:339-352.
9. Sjostrom CD, Lissner L, Sjostrom L: Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS intervention study: Swedish obese subjects. Obes Res 1997, 5:519-530.
10. Thomas PR, ed. Weighing the Options: Criteria for Evaluating Weight-Management Programs. Washington, DC: Institute of Medicine; 1995.
11. Yanovski SZ, Bain RP, Williamson DF: Report of a National Institutes of Health-Centers for Disease Control and prevention workshop on the feasibility of conducting a randomized clinical trial to estimate the long term health effects of intentional weight loss and obese persons. Am J Clin Nutr 1999,69:366-372. In this report, the background and rationale are given for the Study of Health Outcomes of Weight Loss (the SHOW trial) to be sponsored by the National Institutes of Health. This randomized clinical trial is expected to be conducted in 4000 patients, and its observations will provide future guidance for clinical and public health policy decisions regarding obesity treatment.
12. Bray GA: Barriers to the treatment of obesity [editorial]. Ann Intern Med 1991, 115:152-153.
13. Bray GA: Uses and misuses of the new pharmacotherapy of obesity [editorial]. Ann Med 1999, 31:1-3.
14. Weintraub M, Sundaresan PR, Madan M, Schuster B, Balder A, Lasagna L, et al.: Long-term weight control study: I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 1992, 51:586-594.
15. Weintraub M, Sundaresan PR, Schuster B, Ginsberg G, Madan M, Balder A, et al.: Long-term weight control study. II (weeks 34 to 104). an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther 1992, 51:595-601.
16. Weintraub M, Sundaresan PR, Schuster B, Moscucci M, Stein EC: Long-term weight control study: III (weeks 104 to 156): an open-label study of dose adjustment of fenfluramine and phentermine. Clin Pharmacol Ther 1992, 51:602-607.
17. Weintraub M, Sundaresan PR, Schuster B, Averbuch M, Stein EC, Cox C, et al.: Long-term weight control study: IV (weeks 156 to 190): the second double-blind phase. Clin Pharmacol Ther 1992, 51:608-614.
18. Weintraub M, Sundaresan PR, Schuster B, Averbuch M, Stein EC, Byrne L: Long-term weight control study: V (weeks 190 to 120): follow-up of participants after cessation of medication. Clin Pharmacol Ther 1992, 51:615-618.
19. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al.: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337:581-588.
20. American Home Products Unveils Fen-Phen Settlement Plan [news release]. Reuters Health, October 7, 1999.
21. Scheen AJ, Lefebre PJ: Pharmacological treatment of obesity: present status. Int J Obes Related Metab Disord 1999, 23:47-53.
22. Kolanowski J: A risk-benefit assessment of anti-obesity drugs [review]. Drug Saf 1999, 20:119-131.
23. Anderson DA, Wadden TA: Treating the obese patient. Arch Fam Med 1999, 8:156-167. The authors provide guidance in integrating pharmacotherapy into primary care practices.
24. Bray GA, Greenway FL: A review of current and potential drugs for treatment of obesity. Endocr Rev 1999, 20(6):805-875. This comprehensive update on obesity pharmacotherapy includes more than 900 references.
25. Guerciolini R: Mode of action of orlistat. Int J Obes 1997, 21(suppl):S12-S23.
26. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, et al.: Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994, 56:82-85.
27. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al.: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998, 352:167-172. This large multicenter European study demonstrates efficacy and tolerability of orlistat in weight reduction and maintenance for 2 years. The crossover study design is notable.
28. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999, 281:235-242. The study was conducted in 18 centers in the United States. In year 2, dose reduction of orlistat (60 mg three times daily) resulted in more weight gain than the dosage of 120 mg three times daily, but less than with placebo.
29. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al.: Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998, 21:1288-1294. The study demonstrates weight loss and improved glycemic control in diabetic patients receiving orlistat compared with placebo.
30. Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, et al.: Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr 1999, 69:1108-1116. In this report weight loss was initiated by diet during a 6-month lead-in, and then patients were randomized to placebo, 30, 60 or 120 mg, or orlistat three times daily to test efficacy during maintenance.
31. Connoley IP, Heal DJ, Stock MJ: A study in rats of the effects of sibutramine on food intake and thermogenesis [abstract]. Br J Pharmacol 1995, 114:388P.
32. Stock MJ: Sibutramine: a review of the pharmacology of a novel antiobesity agent. Int J Obes 1997, 21(suppl):S25-S29.
33. Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS: Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998, 6:1-11.
34. Seagle HM, Bessessen DH, Hill JO: Effects of Sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res 1998, 6:115-121.
35. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A: Thermogenic effects of Sibutramine in humans. Am J Clin Nutr 1998, 6:1180-1186.
36. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML: Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther 1991, 50:330-337.
37. Ryan DH, Kaiser P, Bray GB. Sibutramine: a novel new agent for obesity treatment. Obes Res 1995, 3:553-559.
38. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K: A double-blind randomized placebo-controlled trial of Sibutramine. Obes Res 1996, 4:263-270.
39. Lean ME: Sibutramine: a review of clinical efficacy. Int J Obes 1997, 21(suppl):S30-S36.
40. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P: Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord 1998, 22:32-38.
41. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E: Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-184. The study is notable for the degree of weight loss associated with combining a very low-calorie diet followed by sibutramine, 10 mg daily.
42. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, et al.: Sibutramine produces dose-related weight loss. Obes Res 1999, 7:189-198. This large, multicenter, placebo-controlled, dose-ranging study demonstrates dose-related weight loss and weight loss-associated improvement in risk factor profiles with sibutramine.
43. Khan MA, Herzog CA, St. Peter JV, Hartley GG, Madlon-Kay R, Dick CD, et al.: The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Eng J Med 1998, 339:713-718. The study reports a case-control analysis of 257 patients exposed to dexfenfluramine, fenfluramine, and phentermine or dexfenfluramine and phentermine and 239 matched control subjects. Echocardiographic evaluation documents the higher prevalence of valvular insufficiency in patients who took medications.
44. Weissman NJ, Tighe JF, Gottdiener JS, Gwynne JT, for the Sustained-Release Dexfenfluramine Study Group: An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med 1998, 339:725-732. Because median duration of exposure was 71 to 72 days, only a small increase in prevalence of valvular regurgitation on echocardiography was demonstrated in this case-control study.
45. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE: A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998,339:719-724. Using a large population-based analysis of the General Practice Research Database, 11 cases of idiopathic valvular regurgitation occurred among 6532 subjects who received dexfenfluramine, compared with no cases among 9281 control subjects and 862 who took phentermine.
46. Wadden TA, Berkowitz RI, Silvestry F, Vogt RA, St. John Sutton MG, Stunkard AJ, et al.: The fen-phen finale: a study of weight loss and valvular heart disease. Obes Res 1998, 6:278-284.
47. Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M, et al.: Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med 1998, 129:870-874.
48. Ryan DH, Bray GA, Helmcke F, Sander G, Volaufova J, Greenway F, et al.: Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res 1999, 7:313-322. This is a notable incidence study of valvulopathy associated with fenfluramine and dexfenfluramine. Among 86 patients who fortuitously underwent echocardiography before receiving appetite suppressants, eight had preexisting regurgitation and 13 had development of new regurgitation. The risk of regurgitation was associated with duration of exposure. Clinical correlation documents only two murmurs among the 13 as asymptomatic patients.
49. Weyer C, Gautier JF, Danforth E: Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes: an update [review]. Diabetes Metab 1999;25:11-21.